Saama Technologies and ICON Commercialization and Outcomes Partner to Unlock the Value of Real World Evidence (RWE)
15 Maio 2018 - 9:00AM
Business Wire
ICON’s Late Phase Experts to Leverage Saama’s
Award-Winning Life Science Analytics Cloud to Support Improved
Commercial Decision Making
Saama Technologies, a leading clinical and health data analytics
company, and ICON plc (NASDAQ: ICLR), a global provider of drug
development and commercialization solutions and services, have
partnered to accelerate the use of Real World Evidence (RWE) across
the product lifecycle and drive mission critical decisions for
medical affairs, reimbursement and commercialization functions.
Biopharmaceutical, medical device and diagnostic companies are
seeking comprehensive RWE technology solutions that can support an
array of RWE applications across the enterprise. Through this
partnership, ICON brings real world data (RWD) strategy and
platform deployment expertise to complement Saama’s deep experience
in utilizing innovative applications such as Natural Language
Processing, Machine Learning and advanced Data Visualization
tools.
The volume of healthcare data continues to grow exponentially
and is forecasted to hit more than two zettabytes by 2020.* This
dramatic increase in the availability of and access to anonymized
electronic patient records requires new approaches for closing the
medical product development and commercialization cycle.
“Saama is very excited about our partnership with ICON, which
further expands our new Life Science Ecosystem,” said Murali
Krishnam, VP Strategic Partnerships and Alliances of Saama.
“Saama’s Artificial Intelligence-based analytics platform, combined
with ICON’s Real World Evidence, Strategy and Analytic (RWESA)
services, will help biopharmaceutical, medical device and
diagnostics companies rapidly deploy a RWE-generating platform.
This will support greater efficiencies in drug development,
providing the RWE needed to inform medical affairs, regulatory and
reimbursement decisions and underscoring the value of the medical
technology to patients and providers.”
“Our partnership with Saama will help us to unlock the real
world data for our sponsors, offering improved clarity regarding
the various types of real world data and how they can best generate
RWE to inform clinical and commercialization strategies,” said
Ramita Tandon, Executive Vice President of ICON’s Commercialization
and Outcomes Division.
Saama’s award-winning Life Science Analytics Cloud (LSAC)
integrates multiple sources of structured, unstructured and
real-time data to optimize clinical and commercialization processes
for deployment in less than 90 days, thus securing better business
outcomes faster. In addition, LSAC further lowers the total cost of
platform ownership significantly for continuous RWE generation and
for managing evolving business needs. This approach integrates
seamlessly with ICON’s unique Real World Intelligence™ approach to
combine RWD and advanced expertise in answering important questions
on patient experience, market access requirements, strategic
evidence planning and roadmap development.
Through this partnership, ICON becomes part of Saama’s recently
announced Life Science Ecosystem, which combines the unparalleled
benefits of Saama’s Life Science Analytics Cloud with the specific
strengths of clinical or real-world data providers.
For information about joining Saama’s Life Science Ecosystem, or
to schedule a demonstration of Saama and ICON’s RWE data analytics
solutions, visit http://www.saama.com/.
About Saama
Saama Technologies is the advanced data and analytics company
delivering actionable business insights for life sciences and the
Global 2000. Saama is singularly focused on driving fast, flexible,
impactful business outcomes for its clients through advanced data
and analytics. Saama’s unique “hybrid” approach integrates focused
solutions and expertise across the life sciences domain, business
consulting, machine learning, automated data management, cloud and
big data technologies. Saama’s approach integrates manual and
disconnected data initiatives into a well-aligned roadmap
facilitating the client’s journey from strategy through solution
implementation to generate business outcomes.
About ICON
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 97 locations in 38 countries and has
approximately 13,380 employees. Further information is available at
www.iconplc.com
*The Digital Universe Driving Data Growth in Healthcare, EMC
Corp. Vertical Industry Brief with Research and Analysis by IDC,
2014
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180515005230/en/
Saama TechnologiesCrystal Black,
408-371-1900crystal.black@saama.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024